RKDA
Arcadia Biosciences, Inc. NASDAQ Listed May 15, 2015$0.73
-2.14%
vs $0.75
Mkt Cap $1.1M
52w Low $0.63
1.7% of range
52w High $6.71
50d MA $0.95
200d MA $2.30
P/E (TTM)
—
EV/EBITDA
—
P/B
0.2x
Debt/Equity
0.0x
ROE
-37.6%
P/FCF
-0.2x
RSI (14)
20.60
ATR (14)
$0.09
Beta
0.72
50d MA
$0.95
200d MA
$2.30
Avg Volume
6.3M
Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.
202 Cousteau Place · Davis, CA 95618 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.66 | -0.98 | -48.5% | 1.52 | +3.9% | -3.3% | -11.6% | +6.2% | +1.4% | -3.6% | — |
| Nov 7, 2025 | AMC | -0.54 | 0.62 | +214.8% | 3.69 | -2.7% | -2.2% | +1.4% | -2.2% | +7.8% | -2.3% | — |
| Aug 14, 2025 | AMC | -0.79 | 0.02 | +102.5% | 4.41 | +1.4% | +5.4% | -3.9% | -1.3% | -0.7% | -0.7% | — |
| May 8, 2025 | AMC | -0.98 | 1.90 | +293.9% | 4.29 | -18.4% | -9.6% | +2.6% | +3.5% | +1.0% | -7.0% | — |
| Mar 20, 2025 | AMC | -0.89 | -2.48 | -178.7% | 3.30 | -3.6% | -4.5% | -0.3% | +9.2% | -3.5% | +2.4% | — |
| Nov 12, 2024 | AMC | -0.77 | -0.87 | -13.0% | 4.24 | -0.7% | -1.2% | -7.9% | -24.9% | -2.1% | +0.0% | — |
| Aug 13, 2024 | AMC | 1.55 | 0.78 | -49.7% | 2.99 | -0.3% | -11.0% | +4.1% | -4.3% | +2.3% | -1.8% | — |
| May 9, 2024 | AMC | -2.52 | -1.78 | +29.4% | 2.08 | -2.9% | -1.0% | -1.0% | +31.4% | +8.2% | +12.8% | — |
| Mar 28, 2024 | AMC | -2.68 | -2.48 | +7.5% | 2.21 | +0.9% | -7.2% | -2.4% | +1.5% | +3.0% | +2.9% | — |
| Nov 9, 2023 | AMC | -2.67 | -1.83 | +31.5% | 3.25 | +3.1% | -3.5% | -2.2% | +4.6% | -4.0% | -1.6% | — |
| Aug 10, 2023 | AMC | -4.92 | -2.64 | +46.3% | 4.42 | +4.5% | -2.7% | -2.1% | +1.7% | -0.2% | -9.4% | — |
| May 15, 2023 | AMC | -6.35 | -3.83 | +39.7% | 4.92 | +0.4% | -2.4% | -2.5% | -1.9% | +0.9% | +0.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.66 | $2.58 | -3.0% | +1.5% | +4.1% | +0.7% | +8.5% | +2.9% |
| May 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.78 | $2.84 | +2.2% | +2.2% | +3.2% | +10.6% | -3.1% | -2.2% |
| Apr 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.09 | $2.10 | +0.5% | +2.9% | -2.8% | -2.4% | -0.5% | -3.0% |
| Aug 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.60 | $3.59 | -0.3% | +0.6% | -3.3% | +0.6% | -0.6% | +13.1% |
| Jul 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.43 | $5.56 | +2.4% | -4.1% | -4.6% | +1.4% | -7.7% | -0.6% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.82 | $4.82 | +0.0% | +0.0% | -0.4% | -0.8% | -2.7% | -1.5% |
| Apr 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.85 | $6.97 | +1.8% | -2.6% | +3.4% | +0.4% | -0.9% | -8.6% |
| Aug 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.40 | $35.60 | +3.5% | -3.3% | +3.4% | -5.2% | +7.1% | -2.4% |
| Jan 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.60 | $42.80 | +2.9% | +13.5% | +17.8% | -19.4% | -8.9% | +11.8% |
| Jun 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $113.20 | $114.40 | +1.1% | +2.1% | +0.0% | -2.4% | -1.8% | +6.1% |
| May 11 | Lake Street | Maintains | Buy → Buy | — | $100.00 | $95.60 | -4.4% | +2.8% | -5.4% | -2.5% | +4.6% | +5.2% |
| Feb 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $143.20 | $146.40 | +2.2% | +5.6% | +50.5% | -19.3% | -17.4% | +5.5% |
| Nov 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $133.12 | $135.60 | +1.9% | +0.1% | +0.3% | -3.6% | +3.4% | -1.1% |
| Aug 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $132.00 | $134.80 | +2.1% | -0.6% | +3.0% | +0.0% | -0.6% | -3.0% |
| Jun 19 | H.C. Wainwright | Maintains | Buy → Buy | — | $326.40 | $334.00 | +2.3% | +2.9% | -1.7% | -3.6% | +5.2% | -3.9% |
| May 12 | Piper Sandler | Downgrade | Overweight → Neutral | — | $640.00 | $664.00 | +3.8% | +2.5% | -8.5% | +0.0% | +1.3% | -6.6% |
| Jun 9 | Credit Suisse | Maintains | Outperform → Outperform | — | $6472.00 | $6624.00 | +2.3% | +1.2% | +2.0% | +4.1% | +0.5% | -3.3% |
No insider trades available.
8-K · 5.02
!!! Very High
Arcadia Biosciences, Inc. -- 8-K 5.02: Executive Change
Jul 2
8-K · 1.01
! Medium
Arcadia Biosciences, Inc. -- 8-K 1.01: Equity Issuance
Arcadia Biosciences raised approximately $4 million through pre-funded warrants and investment options, closing June 12, 2026, providing capital for operations and potential future development initiatives.
Jun 15
8-K · 4.01
!!! Very High
Unknown — 8-K 4.01: Auditor Change / Resignation
RKDA's auditor switch from Deloitte to an unnamed firm raises red flags about potential accounting disagreements or cost concerns, warranting investor scrutiny of the resignation letter's disclosed reasons.
Apr 3
8-K
Unknown — 8-K Filing
Arcadia Biosciences reported 2025 financial results; investor focus should be on revenue trends and guidance for 2026 to assess whether the biotech company is achieving commercialization milestones.
Mar 26
8-K · 5.02
!!! Very High
Arcadia Biosciences, Inc. -- 8-K 5.02: Executive Change
Arcadia Biosciences (RKDA) lost director Albert D. Bolles on February 4, 2026, reducing board experience in compensation oversight and potentially signaling governance transitions.
Feb 6
Valuation
Market Cap
$1.1M
Enterprise Value
-$3.6M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.02x
P/B
0.24x
P/S
0.21x
P/FCF
-0.21x
EV/EBITDA
—
Shares Out
1.4M
Financials (TTM)
Revenue
$4.8M
Net Income
-$9.3M
EBITDA
-$9.3M
Free Cash Flow
-$4.7M
Op Cash Flow
-$4.7M
EPS Basic
$-1.71
EPS Diluted
$-6.83
EPS Forward
$-2.42
Gross Margin
34.5%
Op Margin
-200.8%
Net Margin
-195.9%
Balance Sheet
Total Assets
$6.5M
Total Liab.
$2.4M
Total Equity
$4.1M
Cash
$4.6M
LT Debt
$0
Book Value/Sh
$3.03
Debt/Equity
0.00x
Current Ratio
3.09
Quick Ratio
2.50
Returns & Growth
ROE
-37.6%
ROA
-35.7%
ROIC
-222.8%
Rev Growth YoY
-3.7%
EPS Growth YoY
+66.9%
Price Returns
2W
-12.4%
1M
-26.7%
3M
-43.6%
6M
-65.9%
12M
-84.2%
Technicals
52W High
$6.71
52W Low
$0.63
50d MA
$0.95
200d MA
$2.30
RSI (14)
20.60
ATR (14)
$0.09
Beta
0.72
Avg Volume
6.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$6.00
High
$6.00
Low
$6.00
Median
$6.00
Data updated apr 26, 2026 10:57pm
· Source: financialmodelingprep.com